All treatments
Treatment
Wegovy 2.4 mg FlexTouch solution for injection in pre-filled pen clinical trials
2 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic exploratory (Phase II)
Does the Glucagon-like Peptide 1 (GLP-1) receptor agonist semaglutide reduce alcohol intake in patients with Alcohol Use Disorder and comorbid obesity?
This study is looking into whether a medicine called semaglutide, which is usually for diabetes and weight loss, can help people with alcohol use disorder who also have obesity to drink less alcohol. It's an early-stage study to see if it works.
For: Alcohol Use DisorderDenmark - Ongoing, recruitingTherapeutic use (Phase IV)
Effects of extensive Weight loss on Insulin resistance and Lipid-kinetics in people with obesity and fatty liver Disease
This study looks at how a weight-loss drug, Wegovy, affects fat in the blood and liver in people with obesity and fatty liver disease. Researchers want to see if losing weight helps improve these conditions.
For: ObesityDenmark